Harvard Bioscience Inc.

Susan Luscinski has served as our Chief Operating Officer since August 2004. Ms. Luscinski served as our Chief Financial Officer from August 2001 until August 2004 and Vice President of Finance and Administration from May 1999 until August 2001. Ms. Luscinski served as our Corporate Controller from May 1988 until May 1999 and has served in various other positions at our company and its predecessor since January 1985.

Mr. Uveges joined the Company's Board of Directors in 2004. He is the Founder and Principal of the Tallwood Group. Prior positions include Past President/Chief Executive Officer of TranXenoGen, Chief Operating Officer of BioSource International, Senior Vice President/Chief Financial Officer of NEN Life Science and Chief Financial Officer/Vice President of Gelman Life Sciences. Mr. Uveges is also a member of the Board of Directors of Harvard Biosciences, Inc. Mr. Uveges serves as Chairman of MFIC's Nominating and Corporate Governance Committee.

John F. Kennedy has served as a Director of the Company since October 2000 and currently serves as Chairman of the Audit Committee and is a member of the Compensation Committee. Since June 2006, Mr. Kennedy has served as President and Chief Financial Officer of Nova Ventures Corporation, the management company providing executive management services to the operating companies of Nova Holdings LLC, Nova Analytics Corporation and Nova Technologies Corporation. From July 2002 to June 2006, Mr. Kennedy served as the President and Chief Financial Officer of Nova Analytics Corporation, a worldwide supplier and integrator of analytical instruments. From August 1999 to April 2002, Mr. Kennedy served as the Senior Vice President, Finance, Chief Financial Officer and Treasurer of RSA Security Inc., an e-business security company. Prior to joining RSA Security, Mr. Kennedy was Chief Financial Officer of Decalog, NV, a developer of enterprise investment management software, from 1998 to 1999. From 1993 to 1998, Mr. Kennedy served as Vice President of Finance, Chief Financial Officer and Treasurer of Natural MicroSystems Corporation, a telecommunications company. Mr. Kennedy holds an M.S.B.A. in Accounting from the University of Massachusetts Amherst.

Bob Dishman is a scientist with a long history as a successful biotech operating executive and entrepreneur. In the course of his 30+ years of experience, Bob has become recognized as a leading expert in running biotech companies engaged in drug discovery based on bioseparation, purification, and combinatorial chemistry. Bob is perhaps best known as COO of Sepracor, Inc., managing its work in the "pure isomer" form of major pharmaceuticals, and as the founder and CEO of Arqule, Inc., one of the early combinatorial chemistry companies, both of which went public and achieved multimillion dollar valuations. In addition, Bob was the President and Founder of the Milligen Division of Millipore, focused on DNA and peptide synthesizers and sequencers for analysis and synthesis of biological molecules, and CEO of Biotage, Inc., a company he helped re-direct and take public as Dyax Corp. More recently, Bob has been CEO, Chairman or Board member of four other biotech companies both public and private. Dr. Dishman holds a Ph.D. in Analytical Chemistry, a MS in Chemistry, both from the University of Massachusetts, Amherst, and a BS from the University of New Hampshire, Durham.